Tiburio Therapeutics
Tiburio Therapeutics is a drug development company that develops novel small molecule treatments for potentially life-threatening rare neuroendocrine tumours and endocrine diseases such as non-functioning pituitary adenoma (NFPA).
Tiburio Therapeutics' lead compound, TBR-760, inhibits cell proliferation and thereby shrinks or halts the growth of tumours without the risks associated with more invasive treatments like transsphenoidal surgery (TSS) or radiation.
Relateret nyheder om Tiburio Therapeutics
